TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07506863: A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

Sponsor: Agios Pharmaceuticals, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 54 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,272,888

Rescue Site Savings

+$848,592

Unlock Full NCT07506863 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07506863 Rescue Dossier →